Evidence map›Paper›PMID 23446495›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2013

Hematologic, hepatic, renal, and lipid laboratory monitoring after initiation of combination antiretroviral therapy in the United States, 2000-2010.

Elizabeth L Yanik, Sonia Napravnik, Patrick Ryscavage, Joseph J Eron, Susan L Koletar, Richard D Moore, Anne Zinski, Stephen R Cole, Peter Hunt, Heidi M Crane and 5 more

Abstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Elizabeth L YanikDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27517, USA. elizabeth_yanik@med.unc.edu
Sonia Napravnik
Patrick Ryscavage
Joseph J Eron
Susan L Koletar
Richard D Moore
Anne Zinski
Stephen R Cole
Peter Hunt
Heidi M Crane
James Kahn
William C Mathews
Kenneth H Mayer
Babafemi O Taiwo
Center for Aids Research Network of Integrated Clinical Systems (CNICS) Cohort Study

Funding

Unsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICSR24AI067039 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Michael S. Saag · 2006 to 2026
$99.4M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
North American AIDS Cohorts on Collaboration and Design (NAACCORD)U01AI069918 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Keri Nicole Althoff, RICHARD Douglas MOORE · 2006 to 2026
$65.2M
Training in Sexually Transmitted Infections and HIVT32AI007001 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SENA-SOBERANO, ARLENE C. · 1985 to 2025
$10.9M
Comparative safety of antiretrovirals among HIV-infected patients: minimizing corR01HS018731 · AHRQ · UNIV OF NORTH CAROLINA CHAPEL HILL · PI NAPRAVNIK, SONIA · 2010 to 2012
$1000k
AHRQ HHS R01 HS018731AHRQ HHS R01-HS018731NIAID NIH HHS 5T32-AI007001-35NIAID NIH HHS P30 AI050410NIAID NIH HHS P30-AI50410NIAID NIH HHS R24 AI067039NIAID NIH HHS R24-AI067039NIAID NIH HHS T32 AI007001NIAID NIH HHS U01 AI069918
6 · The paper itself

Abstract

We assessed laboratory monitoring after combination antiretroviral therapy initiation among 3678 patients in a large US multisite clinical cohort, censoring participants at last clinic visit, combination antiretroviral therapy change, or 3 years. Median days (interquartile range) to first hematologic, hepatic, renal, and lipid tests were 30 (18-53), 31 (19-56), 33 (20-59), and 350 (96-1106), respectively. At 1 year, approximately 80% received more than 2 hematologic, hepatic, and renal tests consistent with guidelines. However, only 40% received 1 or more lipid tests. Monitoring was more frequent in specific subgroups, likely reflecting better clinic attendance or clinician perception of higher susceptibility to toxicities.

Indexed as

Antiretroviral Therapy, Highly ActiveDrug MonitoringHematologic TestsAlanine TransaminaseAnti-HIV AgentsAspartate AminotransferasesBilirubinBlood Cell CountCohort StudiesCreatinineFemaleHIV InfectionsHumansKidneyLipidsLiverAlanine TransaminaseAnti-HIV AgentsAspartate AminotransferasesBilirubinCreatinineLipids

Identifiers

PMID23446495
PMCPMC3654034

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.